TNFRSF17 and Miyoshi myopathy: For multiple myeloma (MM), the majority of currently available CAR T-cell products target the B-cell maturation antigen (BCMA), also termed TNFRSF17, which is selectively expressed on mature B lymphocytes and has a relevant role for their survival and proliferation [8].